Bevacizumab, TKI, or PARPi? A targeted approach using composite value-based endpoints and biomarkers to individualize care for platinum-sensitive recurrent ovarian cancer (PSROC)

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2018-06, Vol.149, p.10-11
Main Authors: Foote, J.R., Alvarez-Secord, A., Liang, M.I., Ehrisman, J.A., Cohn, D.E., Jewell, E., Havrilesky, L.J.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2018.04.030